InMed Pharmaceuticals

03/10/2026

InMed's President and CEO, Eric A. Adams, presents at Renmark Financial's Virtual Non-Deal Roadshow.

In the presentation and Q&A, Mr. Adams gives an overview of the company's pharmaceutical programs, including lead drug candidate INM-901 for Alzheimer's disease, and answers these questions:

-How soon do you expect to start INM-901 Phase 1 clinical trial enrollment following a successful IND application?
-Will a Phase 1 clinical trial of INM-901 be conducted in healthy volunteers or in patients living with Alzheimer's disease?
-As INM-901 moves into the clinical development phase, do you expect to increase headcount or will this be outsourced?
-While you've had promising preclinical data of INM-901 so far, what gives you the confidence INM-901's preclinical results will translate similarly into human clinical trials?

Watch the presentation and Q&A here: https://www.inmedpharma.com/learn/inmed-presents-at-renmark-financial-virtual-non-deal-roadshow/

$INM Renmark Financial Communications Inc.

InMed’s President and CEO, Eric A. Adams, presents at Renmark Financial’s Virtual Non-Deal Roadshow on February 26, 2026. In the presentation and Q&A, Mr. Adams gives an overview of the company’s pharmaceutical programs, including lead drug candidate INM-901 for Alzheimer’s disease and the u...

03/09/2026

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

“Looking ahead in 2026, our primary focus is executing activities toward a pre-IND meeting with the FDA in Q3 to discuss the INM-901 program, which we believe will be a key inflection point as we work toward IND submission and initiation of a Phase 1 clinical trial in 2027." ~Eric A. Adams, CEO

Read news release: https://ow.ly/Z1tJ50YrmFe

$INM

03/09/2026

: InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

"We further refined the program’s direction and reinforced our conviction that targeting neuroinflammation is critical to addressing Alzheimer’s disease progression.”

Read news release: https://ow.ly/qe9650YrnaU

$INM

03/09/2026

: InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

-Advancing Alzheimer’s and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling Activities
-Targeting Initiation of Phase 1 Clinical Trial in Alzheimer’s Disease in 2027

Read news release: https://ow.ly/WHSs50Yrmex

$INM

02/26/2026

InMed's CEO, Eric A. Adams, presents at the Renmark Financial Communications Inc. Non-Deal Roadshow.

Eric presents the preclinical studies that demonstrate how INM-901 reduces neuroinflammation associated with Alzheimer's disease. He also talks about the role of CB1 and CB2 receptors in neuroinflammation.

Watch here: https://renmark-drupal.s3.amazonaws.com/vndr/inmed-pharmaceuticals/2026-02-24-14-00-00/index.html

$INM

02/24/2026

-How is InMed's INM-901 different from other Alzheimer’s therapeutics?
-What is INM-901’s mechanism of action? How does INM-901 work?
-How does neuroinflammation affect Alzheimer’s disease?
-What were the results of the INM-901 preclinical studies?
-Does INM-901 reduce amyloid beta plaques?
-What are the next milestones for INM-901?

In this presentation, Mr. Adams speaks about how INM-901 targets the reduction of neuroinflammation. Neuroinflammation is now recognized as a key driver of Alzheimer’s disease development and progression.

In long-term preclinical studies, InMed’s INM-901 significantly reduced neuroinflammatory markers associated with Alzheimer’s disease.

In the video presentation, Mr. Adams also speaks about the upcoming development plans for INM-901 including its preparation for a pre-IND meeting with the FDA.

Watch video here: https://ow.ly/Nlj150YkzM9

$INM

In this presentation, Mr. Adams speaks about how INM-901 targets the reduction of neuroinflammation. Neuroinflammation is now recognized as a key driver of Alzheimer’s disease development and progression.

02/12/2026

InMed today reports financial results for its second quarter of fiscal year 2026, which ended December 31, 2025.

During the quarter, InMed announced the successful completion of pharmacokinetic studies in clinically relevant in vivo models for INM-901. This marked the first preclinical study in which the oral formulation of INM-901 was administered in large animals. The results provide additional data in guiding decisions in the design of a human Phase 1 clinical trial program.

Full news release: https://ow.ly/4PrR50Ye8EZ

$INM

02/12/2026

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

“We are pleased with the steady progress across our pharmaceutical pipeline as we look ahead to pursuing pre-IND meetings with the FDA in 2026. In our INM-901 program, compelling data from the preclinical studies demonstrated a significant reduction in key neuroinflammatory markers, reinforcing neuroinflammation as the central focus of our drug development activities.” ~ Eric A. Adams, CEO

Read full news release here: https://ow.ly/hZEk50Ye8Bw

$INM

12/18/2025

: InMed Announces Results of 2025 Annual General and Special Meeting

Read news release here: https://ow.ly/RGAw50XLfuS

$INM

12/12/2025

InMed presents at the Life Sciences Virtual Investor Forum. CEO Eric A. Adams gives a company update and shares the preclinical data on InMed's lead compound INM-901 for disease.

Presentation available on demand here: https://ow.ly/pXUO50XICg0

$INM

12/04/2025

What is the role of neuroinflammation in Alzheimer's disease development and progression?

This panel of disease experts talk about what to expect in Alzheimer's research in the next few years and why is an important target for novel Alzheimer's treatments.

Discussion here: https://ow.ly/TqVq50XC36B

$INM

Fierce Biotech Webinar “Alzheimer’s Outlook – Neuroinflammation, the Next Step” is now available on demand. InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu, joins a panel of experts to speak about recent breakthroughs in Alzheimer’s disease research and the effects ...

12/01/2025

Summary of InMed's INM-901 Pharmacokinetics Study:

-Over a seven-day dosing period, study demonstrated robust bioavailability with INM-901 achieving what is anticipated to be therapeutic levels of systemic exposure
-Neurological assessments evaluating general attitude, behavior, and motor function revealed no adverse neural or behavioral effects
-InMed has completed additional CMC development to scale manufacturing in preparation for pre-IND meeting with FDA

More here: https://ow.ly/MVST50XAhoY

$INM